{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:18:50Z","timestamp":1785777530876,"version":"3.56.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100016394","name":"Ludwig Center at Harvard","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016394","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,9]]},"abstract":"Abstract<\/jats:title>\n \n Objective<\/jats:title>\n TP53 mutations, including missense and inactivating (frameshift, splice site, and nonsense) mutations, occur in approximately 10% of myeloid neoplasms and confer adverse outcomes. Classification of myeloid neoplasms by World Health Organization and International Consensus Classification standards recognizes the importance of early detection of TP53 mutations. p53 immunohistochemistry (IHC) is a widely accessible method used to detect mutations; however, previous studies have demonstrated variable accuracy, especially for inactivating TP53 mutations. Recently, sequencing using targeted panels has seen increased use. Although highly accurate, sequencing is resource intensive and not universally available.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Using 134 bone marrow samples from patients with acute myeloid leukemia evaluated for TP53 mutation by sequencing, we assessed the concordance of p53 IHC with sequencing as well as the interrater-reliability for IHC intensity and percent positivity.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Consistent with previous studies, we found that p53 IHC was strongly specific and modestly sensitive for missense mutations and that overall performance improved with dedicated hematopathology training. We also found that IHC performed poorly for inactivating mutations and was even variable between cases harboring identical amino acid changes. Low predicted transcriptional activity of p53 missense proteins correlated with a mutant pattern of IHC staining. The status of the second allele and variant allele frequency also affected the accuracy of p53 IHC as a surrogate for TP53 allele status.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Cases of acute myeloid leukemia with TP53 mutations predicted to have low transcriptional activity showed reduced overall survival. Our results demonstrate limited practical utility of p53 IHC for accurate evaluation of TP53 mutation status because of multifactorial confounders.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/ajcp\/aqaf047","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T07:39:37Z","timestamp":1744616377000},"page":"331-341","source":"Crossref","is-referenced-by-count":1,"title":["Detection of TP53<\/i> mutations by immunohistochemistry in acute myeloid leukemia varies with interpreter expertise and mutation status"],"prefix":"10.1093","volume":"164","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4601-5190","authenticated-orcid":false,"given":"Lee P","family":"Richman","sequence":"first","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna F","family":"Waller","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott B","family":"Lovitch","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini","family":"Jambhekar","sequence":"additional","affiliation":[{"name":"Department of Systems Biology, Harvard Medical School , Boston, MA ,","place":["United States"]},{"name":"Ludwig Center at Harvard , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,25]]},"reference":[{"key":"2025091004264960800_CIT0001","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood."},{"key":"2025091004264960800_CIT0002","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med."},{"key":"2025091004264960800_CIT0003","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood-2016-01-693879","article-title":"Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia","volume":"128","author":"Metzeler","year":"2016","journal-title":"Blood."},{"key":"2025091004264960800_CIT0004","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"R\u00fccker","year":"2012","journal-title":"Blood."},{"key":"2025091004264960800_CIT0005","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"N Engl J Med."},{"key":"2025091004264960800_CIT0006","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/cdd.2017.185","article-title":"Mutant p53 partners in crime","volume":"25","author":"Kim","year":"2018","journal-title":"Cell Death Differ."},{"key":"2025091004264960800_CIT0007","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1126\/science.aax3649","article-title":"A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies","volume":"365","author":"Boettcher","year":"2019","journal-title":"Science."},{"key":"2025091004264960800_CIT0008","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.molcel.2018.06.012","article-title":"A systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation","volume":"71","author":"Kotler","year":"2018","journal-title":"Mol Cell."},{"key":"2025091004264960800_CIT0009","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood."},{"key":"2025091004264960800_CIT0010","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/ajcp\/aqae034","article-title":"p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes","volume":"162","author":"Brar","year":"2024","journal-title":"Am J Clin Pathol."},{"key":"2025091004264960800_CIT0011","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/modpathol.2014.153","article-title":"High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome","volume":"28","author":"Cleven","year":"2015","journal-title":"Mod Pathol"},{"key":"2025091004264960800_CIT0012","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/modpathol.2016.206","article-title":"Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis","volume":"30","author":"Fernandez-Pol","year":"2017","journal-title":"Mod Pathol"},{"key":"2025091004264960800_CIT0013","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood.2021013983","article-title":"TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia","volume":"140","author":"Tashakori","year":"2022","journal-title":"Blood."},{"key":"2025091004264960800_CIT0014","doi-asserted-by":"publisher","first-page":"e345","DOI":"10.3324\/haematol.2018.205302","article-title":"TP53 immunohistochemistry correlates with TP53 mutation status and clearance in decitabine-treated patients with myeloid malignancies","volume":"104","author":"Ruzinova","year":"2019","journal-title":"Haematologica."},{"key":"2025091004264960800_CIT0015","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3324\/haematol.2013.098103","article-title":"p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)","volume":"99","author":"Saft","year":"2014","journal-title":"Haematologica."},{"key":"2025091004264960800_CIT0016","first-page":"417","article-title":"Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality","volume":"11","author":"Oliva","year":"2021","journal-title":"Am J Blood Res"},{"key":"2025091004264960800_CIT0017","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/0046-8177(94)90113-9","article-title":"p53 immunohistochemistry: a word of caution","volume":"25","author":"Battifora","year":"1994","journal-title":"Hum Pathol."},{"key":"2025091004264960800_CIT0018","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/humu.22552","article-title":"TP53 mutations in human cancer: database reassessment and prospects for the next decade","volume":"35","author":"Leroy","year":"2014","journal-title":"Hum Mutat."},{"key":"2025091004264960800_CIT0019","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41580-019-0110-x","article-title":"The multiple mechanisms that regulate p53 activity and cell fate","volume":"20","author":"Hafner","year":"2019","journal-title":"Nat Rev Mol Cell Biol."},{"key":"2025091004264960800_CIT0020","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1002\/ijc.2910460515","article-title":"Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro","volume":"46","author":"B\u00e1rtek","year":"1990","journal-title":"Int J Cancer."},{"key":"2025091004264960800_CIT0021","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/8091746","article-title":"Concordance of peripheral blood and bone marrow next-generation sequencing in hematologic neoplasms","volume":"2022","author":"Jumniensuk","year":"2022","journal-title":"Adv Hematol"},{"key":"2025091004264960800_CIT0022","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/s41467-017-01470-y","article-title":"Prevalence and detection of low-allele-fraction variants in clinical cancer samples","volume":"8","author":"Shin","year":"2017","journal-title":"Nat Commun."},{"key":"2025091004264960800_CIT0023","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s12308-020-00431-7","article-title":"p53 immunohistochemistry discriminates between pure erythroid leukemia and reactive erythroid hyperplasia","volume":"14","author":"Alexandres","year":"2021","journal-title":"J Hematopathol."},{"key":"2025091004264960800_CIT0024","doi-asserted-by":"publisher","first-page":"e0119230","DOI":"10.1371\/journal.pone.0119230","article-title":"Reproducibility of variant calls in replicate next generation sequencing experiments","volume":"10","author":"Qi","year":"2015","journal-title":"PLoS One."},{"key":"2025091004264960800_CIT0025","doi-asserted-by":"publisher","first-page":"8424","DOI":"10.1073\/pnas.1431692100","article-title":"Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis","volume":"100","author":"Kato","year":"2003","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2025091004264960800_CIT0026","doi-asserted-by":"publisher","first-page":"5502","DOI":"10.3390\/cancers13215502","article-title":"TP53 combined phenotype score is associated with the clinical outcome of TP53-mutated myelodysplastic syndromes","volume":"13","author":"Yabe","year":"2021","journal-title":"Cancers"},{"key":"2025091004264960800_CIT0027","doi-asserted-by":"publisher","first-page":"e320","DOI":"10.3324\/haematol.2016.143214","article-title":"Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia","volume":"101","author":"McGraw","year":"2016","journal-title":"Haematologica."},{"key":"2025091004264960800_CIT0028","doi-asserted-by":"publisher","first-page":"64910","DOI":"10.18632\/oncotarget.11912","article-title":"Immunohistochemical correlates of TP53 somatic mutations in cancer","volume":"7","author":"Murny\u00e1k","year":"2016","journal-title":"Oncotarget"},{"key":"2025091004264960800_CIT0029","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jmoldx.2016.02.003","article-title":"Validation and implementation of a custom next-generation sequencing clinical assay for hematologic malignancies","volume":"18","author":"Kluk","year":"2016","journal-title":"J Mol Diagn."},{"key":"2025091004264960800_CIT0030","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/ajh.26970","article-title":"Utility of p53 immunohistochemistry as a surrogate for sequencing in myeloid neoplasms: a tale of caution","volume":"99","author":"Nahmod","year":"2024","journal-title":"Am J Hematol."},{"key":"2025091004264960800_CIT0031","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1080\/10428194.2024.2332505","article-title":"Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach","volume":"65","author":"Matthews","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"2025091004264960800_CIT0032","doi-asserted-by":"publisher","first-page":"100004","DOI":"10.1016\/j.bneo.2024.100004","article-title":"Comparison of TP53 mutations in myelodysplasia and acute leukemia suggests divergent roles in initiation and progression","volume":"1","author":"Jambhekar","year":"2024","journal-title":"Blood Neoplasia."},{"key":"2025091004264960800_CIT0033","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med."},{"key":"2025091004264960800_CIT0034","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1182\/blood.2019003439","article-title":"p53 activation during ribosome biogenesis regulates normal erythroid differentiation","volume":"137","author":"Le Goff","year":"2021","journal-title":"Blood."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/164\/3\/331\/63350116\/aqaf047.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/164\/3\/331\/63350116\/aqaf047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T08:26:55Z","timestamp":1757492815000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/164\/3\/331\/8148740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,25]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,5,25]]},"published-print":{"date-parts":[[2025,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqaf047","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,5,25]]}}}